myov Archives - BioTuesdays

Developments

Myovant Sciences updates positive data from Phase 3 prostate cancer trial

Myovant Sciences’ (NASDAQ:MYOV) reported additional positive results from its Phase 3 HERO study of once-daily, oral relugolix in men with advanced prostate cancer. In the primary endpoint responder analysis, 97% of men...

May 29, 2020

Developments

Myovant reports 88% one-year response rate in Phase 3 relugolix extension study

Myovant Sciences (NASDAQ:MYOV) reported that its Phase 3 extension study of once-daily relugolix, in combination with estradiol and norethindrone acetate, achieved a one-year 88% response rate in women with uterine...

February 10, 2020

Developments

Myovant Sciences relugolix meets primary endpoint in Phase 3 prostate cancer trial

Myovant Sciences’ (NASDAQ:MYOV) oral gonadotropin-releasing hormone receptor antagonist, relugolix, met its primary efficacy endpoint in a Phase 3 trial of men with advanced prostate cancer. In the HERO study, nearly...

November 19, 2019

Developments

Myovant Sciences completes recruitment for Phase 3 endometriosis study

Myovant Sciences (NASDAQ:MYOV) completed patient recruitment for its first of two Phase 3 studies of relugolix combination therapy for the treatment of endometriosis-associated pain. Relugolix is a once daily, oral...

August 20, 2019

Markets

SVB Leerink starts Myovant Sciences at OP; PT $26

SVB Leerink initiated coverage of Myovant Sciences (NYSE:MYOV) with an “outperform” rating and $26 price target. The stock closed at $7 on Aug. 16. “Myovant’s lead product, relugolix, is poised to become the second...

August 19, 2019

Developments

Myovant’s relugolix meets primary endpoint in Phase 3 uterine fibroid trial

Myovant Sciences (NASDAQ:MYOV) reported that the second of two Phase 3 studies of relugolix met its primary efficacy endpoint and six key secondary endpoints in women with uterine fibroids. Relugolix is a once daily...

July 24, 2019

Tag - myov

Myovant Sciences updates positive data from Phase 3 prostate cancer trial

Myovant reports 88% one-year response rate in Phase 3 relugolix extension study

Myovant Sciences relugolix meets primary endpoint in Phase 3 prostate cancer trial

Myovant Sciences completes recruitment for Phase 3 endometriosis study

SVB Leerink starts Myovant Sciences at OP; PT $26

Myovant’s relugolix meets primary endpoint in Phase 3 uterine fibroid trial

General

More